Meeting
2023 ASCO Annual Meeting
Correlation of HER2 low status in I-SPY2 with molecular subtype, response, and survival.
Authors
Hope S. Rugo
University of California Comprehensive Cancer Center, San Francisco, CA
Hope S. Rugo , Denise M. Wolf , Christina Yau , Emanuel Petricoin III, Paula R Pohlmann , Lajos Pusztai , W. Fraser Fraser Symmans , Alexander Borowsky , Sandra Finestone , Douglas Yee , Nola Hylton , Laura van 't Veer , Laura Esserman , Angela DeMichele
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Neoadjuvant Therapy
Clinical Trial Registration Number
NCT01042379
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 514)
DOI
10.1200/JCO.2023.41.16_suppl.514
Abstract #
514
Poster Bd #
344
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
HER2-low status discordance between primary and recurrent/metastatic breast cancer in a large-scale cohort.
First Author: Mingxi Lin
Poster
2023 ASCO Annual Meeting
ERBB2 mRNA expression to distinguish HER2-low/neg breast cancer prognosis.
First Author: Yueping Liu
Poster
2023 ASCO Annual Meeting
Correlation between Oncotype DX, Predict, and Nottingham Prognostic Index on HR+, HER2- early breast cancer treatment: The current value of molecular testing.
First Author: Leticia Campoverde
Poster
2023 ASCO Annual Meeting
HER2-low breast cancer brain metastases: Incidence and treatment implications.
First Author: Rania Chehade